Xultophy® Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

Copenhagen, Denmark (ots/PRNewswire) -

New findings from an indirect comparison between Xultophy® and
IGlarLixi published in the Journal of Medical Economics show that
treatment with Xultophy® (insulin degludec/liraglutide) provides
statistically significant greater reductions in blood sugar levels
and body weight compared with IGlarLixi (insulin glargine
U100/lixisenatide), in people with type 2 diabetes who struggle to
achieve desired blood sugar targets with basal insulin alone.[1]

"In the absence of a head-to-head trial between Xultophy® and
IGlarLixi, the solid methodology of this indirect comparison, where
we adjusted for key differences between study designs and patient
populations, allows us to conclude that Xultophy® can deliver greater
reductions in the overall blood sugar levels and weight for people
with type 2 diabetes who are uncontrolled on basal insulin, compared
to IGlarLixi," said lead study author Professor Marc Evans of
University Hospital, Llandough in Cardiff, UK. "This analysis is
based on published data from individual clinical trials which
involved over 700 adults living with type 2 diabetes."

This indirect comparison showed that, within the study population,
people with type 2 diabetes uncontrolled on basal insulin achieved a
0.44% greater reduction of their overall blood sugar levels (HbA1c),
and a 1.42 kg greater weight loss when treated with Xultophy®,
compared to those treated with IGlarLixi, at similar doses of
insulin. Additionally, the analysis found a higher likelihood of
reaching target blood sugar levels (HbA1c <7%) with Xultophy®,
compared to IGlarLixi.[1]

About the analysis

This analysis was an indirect comparison using published data from
phase 3 trials providing evidence for estimating the relative
efficacy and safety of Xultophy® versus IGlarLixi in people with type
2 diabetes uncontrolled on basal insulin. Outcomes of interest were
change in HbA1c, body weight, insulin dose and rate ratio of
hypoglycaemia. Xultophy® was estimated to provide a 0.44% point
reduction in HbA1c compared with IGlarLixi [95%CI: 0.17, 0.71]. Body
weight was reduced by 1.42 kg with Xultophy®, compared to IGlarLixi
[95%CI: 0.35, 2.50].[1]

The results mentioned above were achieved at similar insulin
doses. The rate of severe or blood glucose-confirmed hypoglycaemia
with Xultophy® was approximately half that of IGlarLixi (rate ratio
0.51 [95%CI: 0.29, 0.90]. Rate ratios for severe or BG-confirmed
hypoglycaemia are based on a target of <=3.1 mmol/L in the Xultophy®
trials and <=3.3 mmol/L in the IGlarLixi trial). However, using the
American Diabetes Association definition of documented symptomatic
hypoglycaemia (SMPG <=3.9 mmol/L) the rate was comparable between the
two treatments (rate ratio 1.07 [95%CI: 0.90, 1.28]). Limitations of
this indirect comparison include: differences in study design,
patient characteristics and the definition of hypoglycaemia.[1]

The article published in the Journal of Medical Economics can be
accessed online at: http://dx.doi.org/10.1080/13696998.2017.1409228.

About Xultophy®

Xultophy® is a once-daily single injection fixed-ratio combination
of long-acting insulin degludec and the glucagon-like peptide-1
(GLP-1) receptor agonist liraglutide in one pen. It is indicated for
the treatment of adults with type 2 diabetes mellitus to improve
glycaemic control in combination with oral glucose-lowering medicinal
products when these alone or combined with basal insulin do not
provide adequate glycaemic control. Xultophy® is given once daily by
subcutaneous injection. Xultophy® can be administered at any time of
the day with or without meals, preferably at the same time of the
day.[2]

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 41,700 people in 77 countries and markets its
products in more than 165 countries. For more information, visit
novonordisk.com (https://www.novonordisk.com/), Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.Youtube.com/novonordisk)

Further information

Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Åsa Josefsson

+45-3079-7708

aajf@novonordisk.com

Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Hanna Ögren

+45-3079-8519

haoe@novonordisk.com

Anders Mikkelsen

+45-3079-4461

armk@novonordisk.com

Christina Kjær

+45-3079-3009

cnje@novonordisk.com

Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com

References

1. Evans M, Billings LK, Håkan-Bloch J, et al. An indirect
treatment comparison of the efficacy of insulin degludec/liraglutide
(IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients
with type 2 diabetes uncontrolled on basal insulin. Journal of
Medical Economics. 2017;Published online ahead of print.

2. EMA. Xultophy® Summary of Product Characteristics. Available
at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Produ
ct_Information/human/002647/WC500177657.pdf. Last accessed: November
2017.

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell